Paratek Pharmaceuticals Logo
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 01, 2022 17:45 ET | Paratek Pharmaceuticals
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 21, 2022 16:05 ET | Paratek Pharmaceuticals
BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million
November 03, 2022 16:05 ET | Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021 -- Initiated Rabbit Pilot Efficacy Study...
Paratek Pharmaceuticals Logo
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 01, 2022 16:05 ET | Paratek Pharmaceuticals
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference
November 01, 2022 08:00 ET | Paratek Pharmaceuticals
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract
October 31, 2022 08:00 ET | Paratek Pharmaceuticals
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3
October 25, 2022 08:00 ET | Paratek Pharmaceuticals
BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022
October 13, 2022 16:05 ET | Paratek Pharmaceuticals
Highlights include data from non-clinical and microbiology programs and real-world patient use BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a...
Paratek Pharmaceuticals Logo
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 03, 2022 16:05 ET | Paratek Pharmaceuticals
BOSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)
September 26, 2022 08:30 ET | Paratek Pharmaceuticals
BOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...